Roka Bioscience Inc(NASDAQ:ROKA) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 5, 2016. Company reported revenue of $1.82M. Analysts estimated a revenue of $1.78M. Earnings per share were $-0.43.
Roka Bioscience Inc (ROKA) shares turned negative on Wednesdays trading session with the shares closing down -0.0115 points or -1.29% at a volume of 1,316. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.8788. The peak price level was also seen at $0.8788 while the days lowest was $0.87. Finally the shares closed at $0.8788. The 52-week high of the shares is $2.86 while the 52-week low is $0.5. According to the latest information available, the market cap of the company is $16 M.
Roka Bioscience Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company has launched Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using: culture-based assays immunochemical-based assays and molecular-based assays. The Company’s Atlas instrument is a fully automated molecular diagnostic testing instrument designed to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The Atlas instrument is a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single integrated platform.